Clinical Trials
24 trialsROXI-CAT-II
Regeneron Pharmaceuticals
ROXI-CAT-I
Regeneron Pharmaceuticals
PINPOINT
University of Dublin, Trinity College
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Memorial Sloan Kettering Cancer Center
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Beijing Chao Yang Hospital
Apixaban in Thrombocytopenia
Beth Israel Deaconess Medical Center
AVAJAK
University Hospital, Brest
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
The First Hospital of Jilin University
DOAC
University of Vermont
CATIQ P3
Quercis Pharma AG
ASPIRE
Wake Forest University Health Sciences
VTE-POG
University of Vermont Medical Center
CLOVER
Infanta Leonor University Hospital
HEM-DOAC
Medical University of Gdansk
Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
University Of Perugia
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
State University of New York - Upstate Medical University
The Correlation Between Circulatory Tumor Cells and Venous Thrombosis
Chang Gung Memorial Hospital
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
Medical University of South Carolina
PREVENT-GU
Ottawa Hospital Research Institute
TRIM-Line
Ottawa Hospital Research Institute
STREAM-Line
Ottawa Hospital Research Institute
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
IRCCS Azienda Ospedaliero-Universitaria di Bologna
GynCAT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Identification of Novel Biomarkers to Aid in the Detection of Occult Cancer in Patients With Venous Thromboembolism
Danderyd Hospital